Malignant tumors following renal transplantation;A veseátültetést követoen kialakuló rosszindulatú daganatok

Orvosi Hetilap

Volumn 148, Issue 45, 2007, Pages 2115-2123

  Végso, Gyula ^a,b   Járay, Jeno ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NONE   (Hungary)

Author keywords

Immunosuppression; Malignant tumor; Renal transplantation

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; OKT 3; TACROLIMUS; THYMOCYTE ANTIBODY;

ANUS CANCER; ARTICLE; CANCER RISK; GENITAL TRACT CANCER; HUMAN; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY TRANSPLANTATION; LONG TERM CARE; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; PRECANCER; PROBABILITY; PROGNOSIS; SKIN CANCER; SURVIVAL TIME; TUMOR VIRUS;

EID: 36348956201     PISSN: 00306002     EISSN: 17886120     Source Type: Journal    
DOI: 10.1556/OH.2007.28238     Document Type: Article

References (50)

1. Kauffman, H. M., Cherikh, W. S., McBride, M. A. és mtsai: Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl. Int., 2006, 19, 607-620.
2. Penn, I.: Transmission of cancer from organ donors. Ann. Transplant., 1997, 2, 7-12.
3. Buell, J. F., Beebe, T. M., Trofe, J.: Donor transmitted malignancies. Ann. Transplant., 2004, 9, 53-56.
4. Vegso G., Mathe Z., Peter A. és mtsai: Improving results of renal transplantation with the use of elderly donors: The Budapest experience. Transplant. Proc., 2005, 37, 4225-4227.
5. Fischereder, M., Jauch, K. W.: Prevalence of cancer history prior to renal transplantation. Transpl. Int., 2005, 18, 779-784.
6. Maisonneuve, P., Agodoa, L., Gellert, R. és mtsai: Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet, 1999, 354, 93-99.
7. Penn, I.: Posttransplant malignancies. Transplant. Proc., 1999, 31, 1260-1262.
8. Penn, I.: Cancers in renal transplant recipients. Adv. Ren. Replace Ther., 2000, 7, 147-156.
9. Kasiske, B. L., Snyder, J. J., Gilbertson, D. T. és mtsai: Cancer after kidney transplantation in the United States. Am. J. Transplant., 2004, 4, 905-913.
10. Buell, J. F., Gross, T. G., Woodle, E. S.: Malignancy after transplantation. Transplantation, 2005, 80, S254-264.
11. Adami, J., Gabel, H., Lindelof, B. és mtsai: Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br. J. Cancer, 2003, 89, 1221-1227.
12. Kessler, M., Jay, N., Molle, R. és mtsai: Excess risk of cancer in renal transplant patients. Transpl. Int., 2006, 19, 908-914.
13. Wilson, R. E., Hager, E. B., Hampers, C. L. és mtsai: Immunologic rejection of human cancer transplanted with a renal allograft. N. Engl. J. Med., 1968, 278, 479-483.
14. Taylor, A. L., Marcus, R., Bradley, J. A.: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit. Rev. Oncol. Hematol., 2005, 56, 155-167.
15. Meyer, T, Arndt, R., Nindl, I. és mtsai: Association of human papillomavirus infections with cutaneous tumors in immunosuppressed patients. Transpl. Int., 2003, 16, 146-153.
16. Capello, D., Rossi, D., Gaidano, G.: Post-transplant lymphoproliferative disorders: molecular basis of disease histogenesis and pathogenesis. Hematol. Oncol., 2005, 23, 61-67.
17. Snow, A. L., Martinez, O. M.: Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am. J. Transplant., 2007, 7, 271-277.
18. Fourcade, C., Jarry, L., Mechler, C. és mtsai: Association of B-cell lymphoma and T-cell lymphoma in HTLV1 infection. Ann. Biol. Clin., 1997, 55, 491-493.
19. Lizardi-Cervera, J., Poo, J. L., Romero-Mora, K. és mtsai: Hepatitis C virus infection and non-Hodgkin's lymphoma: a review and case report of nine patients. Ann. Hepatol., 2006, 5, 257-262.
20. Lupberger, J., Hildt, E.: Hepatitis B virus-induced oncogenesis. World J. Gastroenterol., 2007, 13, 74-81.
21. Stankovic-Djordevic, D., Djordevic, N., Tasic, G. és mtsai: Hepatitis C virus genotypes and the development of hepatocellular carcinoma. Chin. J. Dig. Dis., 2007, 8, 42-47.
22. Mbulaiteye, S. M., Engels, E. A.: Kaposi's sarcoma risk among transplant recipients in the United States (1991-2003). Int. J. Cancer, 2006, 119, 2685-2691.
23. Kauffman, H. M., Cherikh, W. S., McBride, M. A. és mtsai: Transplant recipients with a history of a malignancy: risk of recurrent and cle novo cancers. Transplant. Rev., 2005, 19, 55.
24. Kasiske, B. L., Snyder, J. J., Gilbertson, D. T. és mtsai: Cancer after kidney transplantation in the United States. Am. J. Transplant., 2004, 4, 905-913.
25. Desoize, B.: Immuunosuppressive agents are also carcinogens. Crit. Rev. Oncol. Hematol., 2005, 56, 1-4.
26. Taylor, A. L., Watson, C. J. E., Bradley, J. A.: Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Hematol., 2005, 56, 23-46.
27. McGeown, M. G., Douglas, J. F., Middleton, D.: One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporine-based regimes in a single center. In: Cecka, J. M., Terasari, P. I., et al. Clinical Transplants, 2000, Los Angeles: UCLA Immunogenetics Center, 2000, 193.
28. Cherikh, W. S., Kauffman, H. M., Shames, B. D. és mtsai: Association of different inummosuppressive regimens with posttransplant de novo malignancies in liver recipients. Am. J. Transplant., 2005, 5, 392.
29. Cberikh, W. S., Kauffman, H. M., McBride, M. A. és mtsai: Association of the type of induction immunosuppression with post-transplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation, 2003, 76, 1289-1293.
30. Yakupoghu, Y. K., Buell, J. F., Woodle, S. és mtsai: Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant. Proc., 2006, 38, 358-361.
31. Euvrard, S., Kanitakis, J., Claudy, A.: Skin cancers after organ transplantation. N. Engl. J. Med., 2003, 348, 1681-1691.
32. Buell, J. F., Trofe, J., Hanaway, M. J. és mtsai: Immunosuppression and Merkel cell cancer. Transplant. Proc., 2002, 34 1780-1781.
33. Laing, M. E., Moloney, F. J., Comber, H. és mtsai: Malignant melanoma in renal transplant recipients. Br. J. Dermatol., 2006, 155, 857.
34. Penn, I.: Kaposi's sarcoma in transplant recipients. Trans plantation, 1997, 64, 669-673.
35. Wunderlich. H., Wilelm, S., Reichelt, O. és mtsai: Renal cell carcinoma in renal graft recipients and donors: incidence an consequence. Urol. Int., 2001, 67, 24-27.
36. Husted, T. L., Buell, J. F., Hanaway, M. J. és mtsai: De novo sarcomas in solid organ transplant recipients. Transplant Proc., 2002, 34, 1786-1787.
37. Harris, N. L., Jaffe, E. S., Diebold, J. és mtsai: The Work Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the clinical advisory committee meeting. Airlie House, Virginia November 1997. Histopathology, 2000, 36, 69-86.
38. Opelz, G., Dohler, B.: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am. J. Transplant., 2004, 4, 222-230.
39. Dror, Y., Greenberg, M., Taylor, G. és mtsai: Lymphoprofiferative disorders after organ transplantation in children. Transplantation, 1999, 67, 990-998.
40. Manez, R., Breinig, M. K., Linden, P és mtsai: Factors associated with the development of post-transplant lymphoproliferative disease (PTLD) in Epstein-Barr virus (EBV)-seronegative adult liver transplant recipients. Transpl. Int., 1994, 7, S235-237.
41. Caillard, S., Dharnidharka, V., Agodoa, L. és mtsai: Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modem immunosuppression. Transplantation, 2005, 80, 1233-1243.
42. Sancbez-Fructuoso, A., Conesa, J., Perez Flores, I. és mtsai: Conversion to sirolimus in renal transplant patients with tumors. Transplant. Proc., 2006, 38, 2451-2452.
43. Sheil, A. G., Disney, A. P, Mathew, T. H. és mtsai: De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant. Proc., 1993, 25, 1383-1384.
44. Pedotti, P., Cardillo, M., Rossini, G. ş mtsai: Incidence of cancer after kidney transplant: results from the North Italy Transplant Program. Transplantation, 2003, 76, 1448-1451.
45. Howard, R. J., Patton, P. R., Reed, A. I. és mtsai: The changing causes of graft loss and death after kidney transplantation. Transplantation, 2002, 73, 1923-1928.
46. Pope, J. C., Koch, M. O., Bluth, R. F.: Renal cell carcinoma in patients with end stage renal disease: a comparison of clinical significance in patients receiving hemodialysis and those with renal transplant. Urology, 1994, 44, 497-501.
47. Kasiske, B. L., Vazquez, M. A., Harmon, W. E. és mtsai: For the American Society of transplantation. Recommendations for the outpatient surveillance of renal transplant recipients. J. AM. Soc. Nephrol., 2000, 11, S1-S86.
48. Ianbez, L. E., Lucon, M., Nabas, W. C. és mtsai: Renal cell carcinoma in renal transplant patients. Urology, 2007, 69, 462-464.
49. Wang, K., Zbanq, H., Li, Y. és mtsai: Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systemic review. Transplant. Proc., 2004, 36, 2068-2070.
50. Kauffman, H. M., Cherikh, W. S., Cheng, T. és mtsai: Maintenance of immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation, 2005, 80, 883-889.